8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Mar 3, 2026·SEC
Rigel Pharmaceuticals, Inc.(RIGL)Earnings, Financials & Key Ratios
RIGL•NASDAQ
$28.09
$519M mkt cap·1.4× P/E·Price updated May 6, 2026
AboutRigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.Show more
- Revenue$294M+64.1%
- EBITDA$128M+384.0%
- Net Income$367M+1999.1%
- EPS (Diluted)19.48+1867.7%
- Gross Margin93.33%+4.2%
- EBITDA Margin43.46%+194.9%
- Operating Margin42.63%+215.9%
- Net Margin124.72%+1178.8%
- ROE185.94%-65.0%
- ROIC45.82%-92.9%
- Debt/Equity0.14-99.3%
- Interest Coverage17.14+416.3%
RIGL Key Insights
Rigel Pharmaceuticals, Inc. (RIGL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 358.9%
- ✓FCF machine: 25.7% free cash flow margin
- ✓Strong 5Y sales CAGR of 22.1%
- ✓Healthy 5Y average net margin of 10.5%
- ✓Trading at only 1.4x book value
✗Weaknesses
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RIGL Price & Volume
Rigel Pharmaceuticals, Inc. (RIGL) stock price & volume — 10-year historical chart
Loading chart...
RIGL Growth Metrics
Rigel Pharmaceuticals, Inc. (RIGL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years26.12%
5 Years22.06%
3 Years34.76%
TTM47.61%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM879.7%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM804.35%
Return on Capital
10 Years-39.8%
5 Years-6.28%
3 Years15.77%
Last Year48.72%
RIGL Recent Earnings
Rigel Pharmaceuticals, Inc. (RIGL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Mar 3, 2026EPS
$1.14
Est $1.33
-14.3%
Revenue
$70M
Est $69M
+1.6%
Q4 2025
Nov 4, 2025EPS
$1.46
Est $0.93
+57.0%
Revenue
$69M
Est $68M
+1.5%
Q3 2025
Aug 5, 2025EPS
$3.28
Est $1.97
+66.5%
Revenue
$102M
Est $62M
+63.2%
Q2 2025
May 6, 2025EPS
$0.63
Est $0.14
+350.0%
Revenue
$53M
Est $48M
+10.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 3, 2026 | $1.14vs $1.33-14.3% | $70Mvs $69M+1.6% |
| Q4 2025 | Nov 4, 2025 | $1.46vs $0.93+57.0% | $69Mvs $68M+1.5% |
| Q3 2025 | Aug 5, 2025 | $3.28vs $1.97+66.5% | $102Mvs $62M+63.2% |
| Q2 2025 | May 6, 2025 | $0.63vs $0.14+350.0% | $53Mvs $48M+10.4% |
Based on last 12 quarters of dataView full earnings history →
RIGL Peer Comparison
Rigel Pharmaceuticals, Inc. (RIGL) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRTA | 602.39M | 11.19 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 RARE | 2.46B | 25.01 | -4.29 | 20.13% | -85.54% | -9.11% | ||
 HALO | 7.76B | 65.87 | 25.73 | 37.55% | 22.69% | 6.49% | 8.31% | |
 PTCT | 5.39B | 65.04 | 8.36 | 114.51% | 39.44% | 13.02% | ||
 ACAD | 3.78B | 22.35 | 16.43 | 31.85% | 24.94% | 28.47% | 4.16% | 0.07 |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 ARQT | 2.89B | 23.42 | -180.15 | 91.34% | -4.29% | -8.52% | 0.03 |
Compare RIGL vs Peers
Rigel Pharmaceuticals, Inc. (RIGL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RIGL Income Statement
Rigel Pharmaceuticals, Inc. (RIGL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4.48M | 44.51M | 59.29M | 108.62M | 149.24M | 120.24M | 116.88M | 179.28M | 294.28M | 299.77M |
| Revenue Growth % | -78% | 892.62% | 33.2% | 83.21% | 37.39% | -19.43% | -2.79% | 53.38% | 64.15% | 47.61% |
| Cost of Goods Sold | 46.27M | 287K | 906K | 895K | 1.08M | 1.75M | 7.11M | 18.65M | 19.62M | 19.82M |
| COGS % of Revenue | 1031.87% | 0.64% | 1.53% | 0.82% | 0.73% | 1.45% | 6.08% | 10.4% | 6.67% | - |
| Gross Profit | -41.78M▲ 0% | 44.22M▲ 205.8% | 58.38M▲ 32.0% | 107.73M▲ 84.5% | 148.15M▲ 37.5% | 118.49M▼ 20.0% | 109.77M▼ 7.4% | 160.63M▲ 46.3% | 274.66M▲ 71.0% | 279.95M▲ 0% |
| Gross Margin % | -931.87% | 99.36% | 98.47% | 99.18% | 99.27% | 98.55% | 93.92% | 89.6% | 93.33% | 93.39% |
| Gross Profit Growth % | 2.97% | 205.83% | 32.02% | 84.52% | 37.53% | -20.02% | -7.36% | 46.33% | 70.99% | - |
| Operating Expenses | 84.1M | 116.91M | 127.47M | 136.7M | 160.65M | 174.04M | 130.26M | 136.44M | 149.19M | 155.37M |
| OpEx % of Revenue | 1875.56% | 262.65% | 215.01% | 125.85% | 107.65% | 144.74% | 111.45% | 76.1% | 50.7% | - |
| Selling, General & Admin | 37.83M | 70M | 74.59M | 76.6M | 91.89M | 112.45M | 105.74M | 113.06M | 115.9M | 118.84M |
| SG&A % of Revenue | 843.69% | 157.28% | 125.81% | 70.52% | 61.57% | 93.52% | 90.47% | 63.06% | 39.38% | - |
| Research & Development | 46.27M | 46.9M | 52.88M | 60.1M | 65.24M | 60.27M | 24.52M | 23.38M | 33.3M | 36.53M |
| R&D % of Revenue | 1031.87% | 105.38% | 89.2% | 55.33% | 43.71% | 50.13% | 20.98% | 13.04% | 11.31% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 3.52M | 1.32M | 0 | 0 | 0 | 0 |
| Operating Income | -79.62M▲ 0% | -72.68M▲ 8.7% | -69.09M▲ 4.9% | -28.97M▲ 58.1% | -12.5M▲ 56.9% | -55.55M▼ 344.5% | -20.49M▲ 63.1% | 24.19M▲ 218.1% | 125.47M▲ 418.6% | 124.58M▲ 0% |
| Operating Margin % | -1775.56% | -163.3% | -116.53% | -26.67% | -8.37% | -46.2% | -17.53% | 13.49% | 42.63% | 41.56% |
| Operating Income Growth % | -14.16% | 8.71% | 4.94% | 58.07% | 56.87% | -344.54% | 63.11% | 218.06% | 418.63% | - |
| EBITDA | -79.15M | -72.09M | -68.41M | -28.27M | -11.33M | -54.55M | -19.25M | 26.42M | 127.88M | 126.39M |
| EBITDA Margin % | -1765.19% | -161.97% | -115.38% | -26.02% | -7.59% | -45.37% | -16.47% | 14.74% | 43.46% | 42.16% |
| EBITDA Growth % | -15.05% | 8.92% | 5.11% | 58.68% | 59.9% | -381.31% | 64.71% | 237.23% | 384.03% | 172.61% |
| D&A (Non-Cash Add-back) | 465K | 594K | 683K | 706K | 1.16M | 998K | 1.24M | 2.23M | 2.42M | 1.81M |
| EBIT | -77.99M | -70.48M | -66.56M | -28.39M | -12.45M | -54.87M | -18.22M | 26.28M | 125.47M | 112.1M |
| Net Interest Income | 892K | 2.2M | 2.2M | -771K | -4.81M | -3.02M | -4.6M | -5.83M | -3.64M | -2.38M |
| Interest Income | 892K | 2.2M | 2.53M | 582K | 47K | 684K | 2.27M | 2.09M | 3.68M | 4.29M |
| Interest Expense | 0 | 0 | 335K | 1.35M | 4.86M | 3.71M | 6.87M | 7.92M | 7.32M | 4.03M |
| Other Income/Expense | 1.62M | 2.2M | 2.2M | -771K | -4.81M | -3.02M | -4.6M | -5.83M | -3.64M | -2.6M |
| Pretax Income | -77.99M▲ 0% | -70.48M▲ 9.6% | -66.89M▲ 5.1% | -29.74M▲ 55.5% | -17.31M▲ 41.8% | -58.57M▼ 238.4% | -25.09M▲ 57.2% | 18.37M▲ 173.2% | 121.83M▲ 563.3% | 121.97M▲ 0% |
| Pretax Margin % | -1739.34% | -158.35% | -112.83% | -27.38% | -11.6% | -48.71% | -21.47% | 10.24% | 41.4% | 40.69% |
| Income Tax | 0 | 0 | 0 | 0 | 605K | 0 | 0 | 881K | -245.2M | -242.26M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | -3.5% | 0% | 0% | 4.8% | -201.27% | -198.62% |
| Net Income | -77.99M▲ 0% | -70.48M▲ 9.6% | -66.55M▲ 5.6% | -29.74M▲ 55.3% | -17.91M▲ 39.8% | -58.57M▼ 227.0% | -25.09M▲ 57.2% | 17.48M▲ 169.7% | 367.02M▲ 1999.1% | 364.23M▲ 0% |
| Net Margin % | -1739.34% | -158.35% | -112.24% | -27.38% | -12% | -48.71% | -21.47% | 9.75% | 124.72% | 121.5% |
| Net Income Growth % | -12.68% | 9.63% | 5.58% | 55.3% | 39.77% | -226.97% | 57.16% | 169.69% | 1999.08% | 879.7% |
| Net Income (Continuing) | -77.99M | -70.48M | -66.89M | -29.74M | -17.91M | -58.57M | -25.09M | 17.48M | 367.02M | 364.23M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.17▲ 0% | -4.40▲ 28.7% | -4.00▲ 9.1% | -1.80▲ 55.0% | -1.10▲ 38.9% | -3.40▼ 209.1% | -1.44▲ 57.6% | 0.99▲ 168.7% | 19.48▲ 1867.7% | 18.50▲ 0% |
| EPS Growth % | 15.83% | 28.69% | 9.09% | 55% | 38.89% | -209.09% | 57.65% | 168.75% | 1867.68% | 804.35% |
| EPS (Basic) | -6.17 | -4.40 | -4.00 | -1.80 | -1.10 | -3.40 | -1.44 | 0.99 | 20.40 | - |
| Diluted Shares Outstanding | 12.63M | 16.05M | 16.74M | 16.88M | 17.05M | 17.24M | 17.4M | 17.69M | 18.84M | 19.69M |
| Basic Shares Outstanding | 12.63M | 16.05M | 16.72M | 16.88M | 17.05M | 17.24M | 17.4M | 17.58M | 17.99M | 18.41M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RIGL Balance Sheet
Rigel Pharmaceuticals, Inc. (RIGL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 117.43M | 136.99M | 119M | 88.98M | 154.47M | 115.9M | 99.27M | 135.1M | 240.17M | 234.03M |
| Cash & Short-Term Investments | 115.75M | 128.54M | 98.08M | 57.33M | 124.97M | 58.21M | 56.93M | 77.32M | 154.96M | 146.68M |
| Cash Only | 38.29M | 76.32M | 22.52M | 30.37M | 18.89M | 24.46M | 32.79M | 56.75M | 40.58M | 24.41M |
| Short-Term Investments | 77.46M | 52.22M | 75.56M | 26.95M | 106.08M | 33.75M | 24.15M | 20.57M | 114.38M | 122.27M |
| Accounts Receivable | 0 | 4.08M | 10.11M | 15.97M | 15.47M | 40.32M | 30.55M | 41.62M | 51.76M | 49.95M |
| Days Sales Outstanding | - | 33.43 | 62.25 | 53.67 | 37.84 | 122.39 | 95.4 | 84.73 | 64.2 | 57.09 |
| Inventory | 0 | 894K | 1.35M | 1.64M | 6.62M | 9.12M | 5.52M | 6M | 11.51M | 11.65M |
| Days Inventory Outstanding | - | 1.14K | 545.49 | 668.01 | 2.23K | 1.9K | 283.48 | 117.48 | 214.04 | 249.52 |
| Other Current Assets | 1.68M | 3.48M | 0 | 0 | 0 | 8.26M | 6.26M | 10.16M | 21.94M | 25.75M |
| Total Non-Current Assets | 1.68M | 2.12M | 28.56M | 21.39M | 12.86M | 18.38M | 17.96M | 28.87M | 273.43M | 270.58M |
| Property, Plant & Equipment | 875K | 1.39M | 27.87M | 20.57M | 11.89M | 2.79M | 1.03M | 338K | 920K | 785K |
| Fixed Asset Turnover | 5.12x | 32.09x | 2.13x | 5.28x | 12.55x | 43.14x | 113.92x | 530.41x | 319.87x | 296.51x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 14.95M | 13.88M | 27.1M | 24.75M | 24.16M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 803K | 735K | 696K | 824K | 974K | 640K | 3.06M | 1.44M | 1.91M | 9.62M |
| Total Assets | 119.11M▲ 0% | 139.11M▲ 16.8% | 147.57M▲ 6.1% | 110.38M▼ 25.2% | 167.33M▲ 51.6% | 134.28M▼ 19.8% | 117.22M▼ 12.7% | 163.98M▲ 39.9% | 513.59M▲ 213.2% | 504.61M▲ 0% |
| Asset Turnover | 0.04x | 0.32x | 0.40x | 0.98x | 0.89x | 0.90x | 1.00x | 1.09x | 0.57x | 0.82x |
| Asset Growth % | 52.44% | 16.79% | 6.08% | -25.2% | 51.6% | -19.75% | -12.7% | 39.88% | 213.21% | 534.93% |
| Total Current Liabilities | 18.34M | 27.73M | 58.21M | 40.84M | 63.55M | 65.21M | 53.27M | 63.3M | 99.24M | 89.49M |
| Accounts Payable | 2.64M | 6.39M | 4.15M | 3.71M | 3.79M | 22.51M | 7.14M | 3.34M | 7.19M | 4.49M |
| Days Payables Outstanding | 20.79 | 8.13K | 1.67K | 1.51K | 1.28K | 4.7K | 366.64 | 65.36 | 133.77 | 105.04 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 7.23M | 7.27M | 30.43M | 30.5M |
| Deferred Revenue (Current) | -284K | 1.03M | 25.29M | 3.02M | 10.51M | 13.51M | 17.04M | 27.8M | 0 | 30.86M |
| Other Current Liabilities | 284K | 10.36M | 8.82M | 9.59M | 24.2M | 13.86M | 12.32M | 10.14M | 61.62M | 58.99M |
| Current Ratio | 6.40x | 4.94x | 2.04x | 2.18x | 2.43x | 1.78x | 1.86x | 2.13x | 2.42x | 2.42x |
| Quick Ratio | 6.40x | 4.91x | 2.02x | 2.14x | 2.33x | 1.64x | 1.76x | 2.04x | 2.30x | 2.30x |
| Cash Conversion Cycle | - | -6.96K | -1.06K | -790.11 | 988.59 | -2.67K | 12.24 | 136.85 | 144.47 | 201.57 |
| Total Non-Current Liabilities | 128K | 1.5M | 35.54M | 35.51M | 73.4M | 82.68M | 92.6M | 97.39M | 22.88M | 15.22M |
| Long-Term Debt | 0 | 0 | 9.81M | 19.82M | 19.91M | 39.45M | 52.37M | 52.41M | 22.88M | 15.22M |
| Capital Lease Obligations | 0 | 0 | 19.23M | 10.65M | 759K | 972K | 285K | 0 | 0 | 1.27M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 128K | 90K | 5.1M | 5.04M | 52.73M | 42.26M | 39.94M | 44.98M | 0 | 0 |
| Total Liabilities | 18.46M | 29.23M | 93.75M | 76.35M | 136.95M | 147.9M | 145.87M | 160.69M | 122.11M | 104.71M |
| Total Debt | 284K | 0 | 36.31M | 39.09M | 30.57M | 41.55M | 60.58M | 59.97M | 53.3M | 45.72M |
| Net Debt | -38.01M | -76.32M | 13.79M | 8.71M | 11.68M | 17.09M | 27.79M | 3.22M | 12.72M | 21.31M |
| Debt / Equity | 0.00x | - | 0.67x | 1.15x | 1.01x | - | - | 18.24x | 0.14x | 0.14x |
| Debt / EBITDA | - | - | - | - | - | - | - | 2.27x | 0.42x | 0.36x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.12x | 0.10x | 0.10x |
| Interest Coverage | - | - | -198.68x | -20.98x | -2.56x | -14.80x | -2.65x | 3.32x | 17.14x | 27.79x |
| Total Equity | 100.65M▲ 0% | 109.88M▲ 9.2% | 53.81M▼ 51.0% | 34.03M▼ 36.8% | 30.37M▼ 10.7% | -13.62M▼ 144.8% | -28.64M▼ 110.4% | 3.29M▲ 111.5% | 391.48M▲ 11806.3% | 399.9M▲ 0% |
| Equity Growth % | 82.9% | 9.17% | -51.02% | -36.77% | -10.73% | -144.83% | -110.37% | 111.48% | 11806.33% | 15137.59% |
| Book Value per Share | 7.97 | 6.84 | 3.21 | 2.02 | 1.78 | -0.79 | -1.65 | 0.19 | 20.78 | 20.31 |
| Total Shareholders' Equity | 100.65M | 109.88M | 53.81M | 34.03M | 30.37M | -13.62M | -28.64M | 3.29M | 391.48M | 399.9M |
| Common Stock | 147K | 167K | 168K | 169K | 172K | 174K | 17K | 18K | 18K | 18K |
| Retained Earnings | -1.14B | -1.21B | -1.28B | -1.31B | -1.32B | -1.38B | -1.41B | -1.39B | -1.02B | -1.01B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -82K | -24K | 23K | -4K | -102K | -153K | 8K | 10K | 181K | -128K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RIGL Cash Flow Statement
Rigel Pharmaceuticals, Inc. (RIGL) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -77.56M | -58.83M | -41.51M | -52.19M | 5.88M | -73.76M | -5.74M | 31.47M | 75.66M | 75.66M |
| Operating CF Margin % | -1729.64% | -132.17% | -70.01% | -48.04% | 3.94% | -61.34% | -4.91% | 17.55% | 25.71% | - |
| Operating CF Growth % | -2.2% | 24.15% | 29.44% | -25.72% | 111.26% | -1354.81% | 92.21% | 647.99% | 140.4% | 10479.14% |
| Net Income | -77.99M | -70.48M | -66.89M | -29.74M | -17.91M | -58.57M | -25.09M | 17.48M | 367.02M | 364.23M |
| Depreciation & Amortization | 465K | 594K | 683K | 706K | 1.16M | 998K | 1.24M | 2.23M | 2.42M | 2.41M |
| Stock-Based Compensation | 5.99M | 7.7M | 9.12M | 7.3M | 9.49M | 12.38M | 8.81M | 12.39M | 12.71M | 12.84M |
| Deferred Taxes | -1.08M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -245.85M | -243.28M |
| Other Non-Cash Items | 495K | -766K | -1.07M | -122K | 3.43M | 481K | -213K | -788K | -41.13M | -56.94M |
| Working Capital Changes | -5.43M | 4.12M | 16.66M | -30.32M | 9.72M | -29.05M | 9.52M | 153K | -19.51M | 9K |
| Change in Receivables | 0 | -4.08M | -6.03M | -5.86M | 501K | -24.85M | 9.77M | -11.06M | -10.15M | -8.4M |
| Change in Inventory | 0 | -839K | -366K | -126K | -4.88M | -2.38M | 1.17M | 764K | -5.63M | -7.63M |
| Change in Payables | -2.95M | 3.75M | -2.24M | -331K | 41K | 3.79M | -366K | -3.8M | 3.85M | 3.98M |
| Cash from Investing | -19.47M | 24.96M | -23.66M | 47.47M | -80.04M | 72.78M | -4.3M | 4.13M | -92.36M | -89.79M |
| Capital Expenditures | -164K | -1.11M | -1.46M | -1.26M | -627K | -450K | -15M | -396K | 0 | 0 |
| CapEx % of Revenue | 3.66% | 2.48% | 2.45% | 1.16% | 0.42% | 0.37% | 12.83% | 0.22% | - | - |
| Acquisitions | 732K | 1.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 732K | -1.11M | 0 | 0 | 0 | 893K | 259K | 98K | 0 | -33.16M |
| Cash from Financing | 117.69M | 71.89M | 11.37M | 12.57M | 62.67M | 6.55M | 18.37M | -11.64M | 601K | -10.8M |
| Debt Issued (Net) | 0 | 0 | 9.79M | 9.97M | 0 | 19.54M | 19.95M | 0 | -7.5M | -7.5M |
| Equity Issued (Net) | 114.18M | 67.16M | 0 | 0 | 0 | 0 | 0 | -10M | 8.1M | 3.35M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -10M | 0 | -3.74M |
| Other Financing | 3.51M | 4.73M | 1.58M | 2.6M | 62.67M | -12.99M | -1.58M | -1.64M | 0 | -6.65M |
| Net Change in Cash | 20.66M▲ 0% | 38.03M▲ 84.1% | -53.8M▼ 241.5% | 7.85M▲ 114.6% | -11.48M▼ 246.2% | 5.57M▲ 148.5% | 8.33M▲ 49.5% | 23.96M▲ 187.7% | -16.11M▼ 167.2% | -21.32M▲ 0% |
| Free Cash Flow | -77.72M▲ 0% | -59.93M▲ 22.9% | -42.97M▲ 28.3% | -53.45M▼ 24.4% | 5.25M▲ 109.8% | -74.21M▼ 1513.2% | -20.74M▲ 72.0% | 31.07M▲ 249.8% | 75.66M▲ 143.5% | 79.27M▲ 0% |
| FCF Margin % | -1733.3% | -134.65% | -72.47% | -49.2% | 3.52% | -61.72% | -17.75% | 17.33% | 25.71% | 26.44% |
| FCF Growth % | -1.34% | 22.89% | 28.31% | -24.4% | 109.82% | -1513.22% | 72.05% | 249.81% | 143.46% | 124.36% |
| FCF per Share | -6.15 | -3.73 | -2.57 | -3.17 | 0.31 | -4.30 | -1.19 | 1.76 | 4.02 | 4.02 |
| FCF Conversion (FCF/Net Income) | 0.99x | 0.83x | 0.62x | 1.75x | -0.33x | 1.26x | 0.23x | 1.80x | 0.21x | 0.22x |
| Interest Paid | 0 | 0 | 137K | 1.18M | 1.5M | 2.5M | 5.85M | 7.04M | 0 | 1.68M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 331K | 0 | 0 |
RIGL Key Ratios
Rigel Pharmaceuticals, Inc. (RIGL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -100.2% | -66.96% | -81.31% | -67.72% | -55.63% | -699.05% | - | 531.78% | 185.94% | 147.03% |
| Return on Invested Capital (ROIC) | -115.39% | -113.34% | -102.45% | -39.38% | -22.11% | -183.02% | -1170.02% | 641.58% | 45.82% | 45.82% |
| Gross Margin | -931.87% | 99.36% | 98.47% | 99.18% | 99.27% | 98.55% | 93.92% | 89.6% | 93.33% | 93.39% |
| Net Margin | -1739.34% | -158.35% | -112.24% | -27.38% | -12% | -48.71% | -21.47% | 9.75% | 124.72% | 121.5% |
| Debt / Equity | 0.00x | - | 0.67x | 1.15x | 1.01x | - | - | 18.24x | 0.14x | 0.14x |
| Interest Coverage | - | - | -198.68x | -20.98x | -2.56x | -14.80x | -2.65x | 3.32x | 17.14x | 27.79x |
| FCF Conversion | 0.99x | 0.83x | 0.62x | 1.75x | -0.33x | 1.26x | 0.23x | 1.80x | 0.21x | 0.22x |
| Revenue Growth | -78% | 892.62% | 33.2% | 83.21% | 37.39% | -19.43% | -2.79% | 53.38% | 64.15% | 47.61% |
RIGL SEC Filings & Documents
Rigel Pharmaceuticals, Inc. (RIGL) SEC filings — annual & quarterly reports (10-K, 10-Q)
RIGL Frequently Asked Questions
Rigel Pharmaceuticals, Inc. (RIGL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rigel Pharmaceuticals, Inc. (RIGL) reported $299.8M in revenue for fiscal year 2025. This represents a 3237% increase from $9.0M in 1999.
Rigel Pharmaceuticals, Inc. (RIGL) grew revenue by 64.1% over the past year. This is strong growth.
Yes, Rigel Pharmaceuticals, Inc. (RIGL) is profitable, generating $364.2M in net income for fiscal year 2025 (124.7% net margin).
Dividend & Returns
Rigel Pharmaceuticals, Inc. (RIGL) has a return on equity (ROE) of 185.9%. This is excellent, indicating efficient use of shareholder capital.
Rigel Pharmaceuticals, Inc. (RIGL) generated $79.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More RIGL
Rigel Pharmaceuticals, Inc. (RIGL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates